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Abstract: Symptomatic uncomplicated diverticular disease (SUDD) is a syndrome characterized by
recurrent abdominal symptoms in patients with colonic diverticula. There is some evidence that a
high-fiber diet or supplemental fibers may reduce symptoms in SUDD patients and a high-fiber diet
is commonly suggested for these patients. This systematic review aims to update the evidence on
the efficacy of fiber treatment in SUDD, in terms of a reduction in symptoms and the prevention
of acute diverticulitis. According to PRISMA, we identified studies on SUDD patients treated with
fibers (PubMed and Scopus). The quality of these studies was evaluated by the Jadad scale. The main
outcome measures were a reduction of abdominal symptoms and the prevention of acute diverticulitis.
Nineteen studies were included, nine with dietary fiber and 10 with supplemental fiber, with a high
heterogeneity concerning the quantity and quality of fibers employed. Single studies suggest that
fibers, both dietary and supplemental, could be beneficial in SUDD, even if the quality is very low,
with just one study yielding an optimal score. The presence of substantial methodological limitations,
the heterogeneity of the therapeutic regimens employed, and the lack of ad hoc designed studies, did
not permit a summary of the outcome measure. Thus, the benefit of dietary or supplemental fiber in
SUDD patients still needs to be established.
Keywords: diverticular disease; dietary fiber; supplemental fiber; symptomatic uncomplicated
diverticular disease
1. Introduction
Colonic diverticula are common in Western countries, affecting up to 60% of subjects over
70 years of age [1]. In about 80% of patients, colonic diverticula remain asymptomatic (diverticulosis),
while approximately 20% of patients may develop abdominal symptoms (symptomatic uncomplicated
diverticular disease, SUDD) and, eventually, complications such as bouts of diverticulitis or bleeding [2].
SUDD has been defined as a syndrome which is characterized by recurrent abdominal symptoms (i.e.,
abdominal pain and bloating resembling or overlapping those present in irritable bowel syndrome),
attributed to diverticula in the absence of macroscopically evident alterations, other than the presence
of diverticula [3,4]. The impact of these complaints is variable, and the severity and frequency
of symptoms may range from mild and rare episodes, to a severe, chronic, recurrent disorder,
impacting daily activities and the quality of life of patients [5,6]. About 4% of patients develop
acute diverticulitis, an inflammatory process that may result in complications in about 15% of patients,
with the development of abscesses, perforation, fistula, obstruction, or peritonitis [7]. A recurrence of
diverticulitis after the first episode has been reported to occur in 15%–30% of patients [8,9].
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The main goals of managing SUDD are both the reduction of abdominal symptoms and the
prevention of acute diverticulitis. Even if recommendations for the treatment of SUDD have been issued
by the medical societies of various countries [3,10–13], a standard therapeutic approach still remains to
be defined. Fibers have been suggested for the treatment of SUDD patients, but the therapeutic benefit
is not yet fully understood. Fibers might confer benefits by increasing fecal mass and regularizing
bowel movements, as well as acting as prebiotics in the colon, favoring health-promoting species of the
intestinal microbiota [14]. Fibers are defined as the edible parts of plants or the analogous carbohydrates
that are resistant to digestion and absorption in the human small intestine, with complete or partial
fermentation in the colon [15]. Fiber intake may be achieved by consuming fruits, vegetables, and
cereal grains (dietary fibers), and/or by diet supplementation with specific commercial preparations
containing fibers (supplemental fibers).
A previous systematic review assessed whether a high-fiber diet can improve symptoms or
prevent complications of diverticular disease. Few studies were identified, and the authors concluded
that evidence for a therapeutic benefit of a high-fiber diet in the treatment of diverticular disease is
poor [16].
This systematic review aims to update the evidence on the efficacy of treatment with fiber in
SUDD, in terms of the reduction of symptoms and the prevention of acute diverticulitis.
2. Methods
2.1. Study Selection
The search was conducted according to the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines [17]. The electronic databases PubMed MEDLINE (U.S.
National Library of Medicine, Bethesda, MD, USA) and Scopus were systematically searched according
to the following search strategy, using the following MesH terms:
(((“diverticulum” [MeSH Terms] OR “diverticulum” [All Fields] OR “diverticulosis” [All Fields])
OR diverticular [All Fields] OR (“diverticulum” [MeSH Terms] OR “diverticulum” [All Fields] OR
“diverticula” [All Fields]) OR (“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields])) AND
((“colon” [MeSH Terms] OR “colon” [All Fields]) OR (“colon” [MeSH Terms] OR “colon” [All Fields]
OR “colonic” [All Fields]) OR (“colon, sigmoid” [MeSH Terms] OR (“colon” [All Fields] AND “sigmoid”
[All Fields]) OR “sigmoid colon” [All Fields] OR “sigmoid” [All Fields])) AND ((“dietary fiber”
[MeSH Terms] OR (“dietary” [All Fields] AND “fiber” [All Fields]) OR “dietary fiber” [All Fields]
OR “fiber” [All Fields]) OR fibre [All Fields] OR (“diet” [MeSH Terms] OR “diet” [All Fields] OR
“dietary” [All Fields]) OR insoluble [All Fields] OR soluble [All Fields] OR (“fruit” [MeSH Terms]
OR “fruit” [All Fields]) OR (“vegetables” [MeSH Terms] OR “vegetables” [All Fields] OR “vegetable”
[All Fields]) OR (“(1-6)-alpha-glucomannan” [Supplement *] OR “(1-6)-alpha-glucomannan” [All
Fields] OR “glucomannan” [All Fields]) OR (“starch” [MeSH Terms] OR “starch” [All Fields]) OR
fructooligosaccharides [All Fields] OR bran [All Fields] OR (“inulin” [MeSH Terms] OR “inulin” [All
Fields]) OR (“psyllium” [MeSH Terms] OR “psyllium” [All Fields]))) AND (“humans” [MeSH Terms]
AND (English [lang] OR French [lang] OR German [lang] OR Italian [lang] OR Spanish [lang]) AND
“adult” [MeSH Terms]) AND (“therapy” [Subheading] OR “therapy” [All Fields] OR “treatment” [All
Fields] OR “therapeutics” [MeSH Terms] OR “therapeutics” [All Fields]) AND (“humans” [MeSH
Terms] AND (English [lang] OR French [lang] OR German [lang] OR Italian [lang] OR Spanish [lang])
AND “adult” [MeSH Terms]).
The search strategy excluded reviews, meta-analyses, case reports, and animal studies.
The following study types were included: randomized controlled trials (blinded and/or placebo-
controlled), open randomized clinical trials, and non-randomized open studies. Pediatric subjects
were excluded from this review. No publication data restriction was imposed. Reports published in
English, German, French, Italian, and Spanish were considered.
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Clinical studies published up to 7 October 2016 were considered for inclusion in this review, if they
described in adults (>18 years) with SUDD, the efficacy of fiber treatment with respect to the baseline
(i) on reduction or remission of abdominal symptoms; and/or (ii) on prevention of acute diverticulitis.
Potentially relevant articles were independently screened for eligibility in an un-blinded
standardized manner by the two reviewers (M.C., E.L.), initially by abstract, and then by full text
when necessary, in order to determine whether they met the inclusion criteria. Reviews, letters, books,
and/or editorials were excluded on the basis of the abstract and/or title; in other cases, the judgement
of inclusion/exclusion was based on an evaluation of the full-text. Disagreement between reviewers
was resolved by discussion. The reference lists of the identified articles, as well as of the identified
relevant reviews, were manually searched for additional studies that may have been overlooked using
a computer-assisted search strategy.
2.2. Data Extraction
We developed a data extraction sheet, pilot-tested it on three randomly-selected included studies,
and refined it accordingly. One review author (M.C.) extracted the data from the included studies
and the second author (E.L.) checked the extracted data. Disagreements were resolved by discussion
between the two review authors. The following information was extracted from each included paper:
(1) author and year of publication; (2) characteristics of fibers; (3) characteristics of study participants
(number, mean age, and gender); (4) diagnosis of SUDD; (5) study type and treatment arms; (6) type
of intervention; (7) follow-up; (8) outcome measure (reduction of abdominal symptoms; occurrence
of acute diverticulitis); (9) efficacy of intervention; (10) adverse effects of fiber arms; (11) single or
multiple centers.
The diagnosis of SUDD was considered appropriate when patients with colonic diverticula had
recurrent abdominal symptoms such as abdominal pain, which were eventually associated with
bloating or bowel habit alteration [3]. Studies which did not completely fulfill this definition were not
excluded a priori, but the specific clinical settings were singularly extracted and described in detail.
For the purpose of this paper, dietary fibers were defined as the intake of food fibers in fruits,
vegetables, and cereal grains. A high-fiber diet has been defined as at least a 30 g daily intake of
dietary fibers [18]. When indicated, the amount of daily fiber intake was extracted from each paper.
Supplemental fibers were defined as diet supplementation with specific commercial preparations
containing one or more types of fiber.
2.3. Statistical Analysis
Originally, a meta-analysis was planned in order to provide a numerical estimate of the overall
effect of interest, for which the outcome measure (effect size) comprised the proportion of patients
who showed a positive response to fiber treatment with respect to the baseline, or with respect to
controls, defined as the reduction of abdominal symptoms and prevention of acute diverticulitis. Due
to the heterogeneity of the retrieved studies and their low quality, a meta-analysis was not considered
applicable. The efficacy of the interventions reported in the retrieved studies was described in a
qualitative manner.
2.4. Quality Assessment
The two reviewers evaluated the quality of all of the included studies, using the Jadad scale
for randomized controlled trials [19]. This scale awards a maximum of five points to each study.
The considered categories are randomization, blinding of outcome assessment, description of
withdrawals and dropouts, and description and appropriateness of randomization and blinding.
A study can be awarded a maximum of one point for each category (Table S1). Discrepancies in the
quality assessment were discussed and resolved by the two reviewers.
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3. Results
3.1. Search Results
The electronic search study identified a total of 374 records from electronic databases, 351 of
which were unique (Figure 1).
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Figure 1. Flow-chart of study selection.
Manu l searching of a reference list of potentially re evant p pers contributed another four articles.
The rticles were screened on th basis of the title and abstract and, after application of the inclusion
and exclusion criteria, 21 articles were retrieved for a full-paper evaluation. Of these 21 papers, 19 met
the eligibility criteria and were subjected to data extraction. Two studies were excluded because
the outcome was not pertinent to the present study purpose, since it only evaluated constipated
patients [20,21]. Thus, 19 articles were included for qualitative synthesis (Table 1).
Table 1. Type of fibers and dosage used in the included studies.
Author, Year (Reference) Type of Fibers and Dosage
Dietary
Lahner E., 2012 [ 2] Dietary fiber (a least 30 gr/day)
Annibale B., 2011 [23] Dietary fiber (at least 30 gr/day)
Colecchia A., 2007 [24] Dietary fiber (at least 20 gr/day)
Smits B.J., 1990 [25] Dietary fiber (30–40 gr/day)
Leahy A.L., 1985 [26] Dietary fiber (>25 gr/day)
Hyland J.M.P., 1980 [27] Dietary fiber (37.9 gr/day)
Brodribb A.J.M., 1977 [28] Bran crispbread (6.7 gr/day) Wheat crispbread (0.6 gr/day)
Plumley P.F., 73 [29] High-fiber crispbre d (96 gr/day total unavailable fraction)
Painter N.S., 1972 [30] High-residue, low sugar diet with unprocessed bran (12–14 gr/day)
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Table 1. Cont.
Author, Year (Reference) Type of Fibers and Dosage
Supplemental
Lanas A., 2013 [31] Plantago ovata (7 gr/day)
Latella G., 2003 [32] Glucomannan (4 gr/day)
Papi C., 1995 [33] Glucomannan (2 gr/day)
Papi C., 1992 [34] Glucomannan (2 gr/day)
Thorburn H.A., 1992 [35] Ispaghula husk (7 gr/day)
Ornstein M.H., 1981 [36] Bran (6.99 g/day) Ispaghula (9.04 gr/day)
Eastwood M.A., 1978 [37] Bran (20 g/day) Isphaghula (2 sachets/day)
Hodgson W.J.B., 1977 [38] Methylcellulose (1000 mg/day)
Brodribb A.J.M., 1976 [39] Wheat bran (24 gr/day)
Taylor I., 1976 [40] High roughage diet with bran supplement Bran (18 gr/day)
3.2. Quality Assessment
Details of the quality assessment of the included studies are given in Supplementary Table S1 (see
Supplementary material). Of the 19 studies included, six achieved 0 points [26,27,35,36,39,40], three
achieved 1 point [25,29,30], two achieved 2 points [28,38], seven achieved 3 points [22–24,31,33,34,36],
and only one achieved 5 points [33], according to Jadad scale.
3.3. Characteristics of Included Studies
The main characteristics of the 19 included studies are summarized in Table 2. Considering the
high heterogeneity of the fibers used, studies are grouped on the basis of dietary (nine articles) or
supplemental fibers (ten articles).
Table 2. Main characteristics of the 19 selected studies on fibers in symptomatic uncomplicated
diverticular disease (SUDD).
Author, Year (Reference) N/F/MeanAge
Diagnosis of
SUDD Study Type/Arms
Single Center
Yes/No
Dietary
Lahner E., 2012 [22] 44/35/66 App Open RCT/2 No
Annibale B., 2011 [23] 50/32/65 App Open RCT/3 No
Colecchia A., 2007 [24] 307/189/62 App Open RCT/2 No
Smits B.J., 1990 [25] 43/28/59 App Open RCT/2 Yes
Leahy A.L., 1985 [26] 56/-/- App Retrospective study/2 Yes
Hyland J.M.P., 1980 [27] 100/73/67 NcApp 1 Retrospective study/1 Yes
Brodribb A.J.M., 1977 [28] 18/9/60 App Double-blind RCT Yes
Plumley P.F., 1973 [29] 48/-/71 NcApp 2 Prospective interventional, partly cross-over study/2 Yes
Painter N.S., 1972 [30] 70/25/60 App Prospective interventional study, not controlled/1 Yes
Supplemental
Lanas A., 2013 [31] 165/59/54 NcApp 3 Open RCT/2 No
Latella G., 2003 [32] 968/501/63 App Open RCT/2 No
Papi C., 1995 [33] 168/100/62 App Double-blind placebo controlled/2 No
Papi C., 1992 [34] 217/112/65 App Open RCT/2 No
Thorburn H.A., 1992 [35] 10/4/66 NcApp 4 Open/1 Yes
Ornstein M.H., 1981 [36] 58/36/64 App Double-blind, cross-over, RCT/3 No
Eastwood M.A., 1978 [37] 31/-/60 NcApp 5 Prospective, not randomized/3 Yes
Hodgson W.J.B., 1977 [38] 30/18/60 App Double-blind, cross-over RCT/2 Yes
Brodribb A.J.M., 1976 [39] 40/-/- App Prospective, not controlled/1 Yes
Taylor I., 1976 [40] 20/-/- NcApp 6 Cross-over RCT Yes
App: appropriate; NcApp: not completely appropriate; F: female gender; N: number of patients; RCT: randomized
controlled trial; 1 an unspecified number of pts with acute diverticulitis were included; 2 4 pts with diverticulosis
were included; 3 pts with a recent episode of colonic diverticulitis, current in remission were included, 4 3 pts with
diverticulosis were included; 5 an unspecified number of pts with diverticulosis were included; 6 8 pts with acute
diverticulitis were included.
In thirteen studies, SUDD was appropriately diagnosed [22–26,28,30,32–34,36,38,39], while in six
studies, the diagnosis was not completely appropriated [27,29,35,37,40] (see Table 2). The latter studies
include three in which SUDD patients with diverticulosis were included [29,35,37], and in the other
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two studies, SUDD patients with acute diverticulitis were included [27–40]. In one study, patients
who had reported a recent episode of colonic diverticulitis, but were currently in remission, were
included [31].
3.4. Dietary Fiber
Articles concerning dietary fibers were performed over a period of 40 years, from 1972 to 2012, and
only three of them were published in the last 10 years [22–24]. Six of these were single center studies
and three were multicenter studies [22–24]. Six studies were conducted in the United Kingdom [25–30]
and three were completed in Italy [22–24].
An overall number of 736 patients with SUDD were investigated, for which the female gender
was slightly prevalent (n = 391), but in two articles [26–29], the gender of the patients was lacking.
Patients had a mean age of 64 years, ranging from 59 to 71 years. In one study, the age of patients was
lacking [26].
With regard to the study type, four were randomized controlled open trials [22–25], two were
retrospective studies [26,27], one was a double-blind RCT [28], one was a prospective partly cross-over
study [29], and the remaining one was an un-controlled study [30].
With regard to the fibers used, in the majority of the studies, patients were treated with dietary
fibers [22–27], in two articles crispbread was used [28,29], and in the last study, a high residue, low sugar
with unprocessed bran was utilized [30]. In addition, the amount of dietary fiber utilized was variable,
ranging from 20 [24] to 96 gr/day [29]. In five studies, a high-fiber diet was employed [22,23,25,27,29],
but in the other studies, the dosage of fiber seemed to be lower than 30 gr daily [24,26,28,30].
Unfortunately, it was not possible to assess the proportion of soluble or insoluble fibers for each
dietary regimen, since its exact composition was not reported.
The follow-up protocol was very variable between studies, ranging from three [25–28] to
65 months [27]. Also, the interventions were variable between studies: in four studies, the dietary fiber
was a control arm and was compared in two articles to symbiotic preparations [22,23], in another it was
compared to rifaximin [24], and in the last it was compared to lactulose [25]. In one study, a high-fiber
diet was compared to one which was not high in fiber [26], and in two studies, high-fiber crispbread was
compared to lower fiber crispbread [28,29]. One study used a high-fiber diet without a control arm [27],
and the other study used a high-residue, low sugar diet with unprocessed bran [30]. With regard to
the outcome measures, seven articles assessed the reduction of abdominal symptoms [22,23,25,27–30],
and two assessed the reduction of symptoms and/or complications.
Two of the most recent open RCT studies compared a high-fiber diet with the combined treatment
of a high-fiber diet and a symbiotic preparation [22,23]. In the first study, both treatments significantly
reduced abdominal pain [22], whereas in the second, the high-fiber diet alone did not improve
abdominal symptoms, compared to the baseline [23]. Another open RCT study compared a high-fiber
diet with the combination of a high-fiber diet and rifaximin, and showed that both treatments
significantly improved abdominal symptoms, compared to the baseline [24]. The occurrence of
diverticulitis was reduced during the administration of a high-fiber diet in comparison to one which
was not high in fiber, at a follow-up of 65 months [26]. Another study showed a similar frequency of
diverticulitis occurrence in both treatment arms, for both dietary fiber and dietary fiber plus rifaximin,
after 24 months [24]. Table 3 summarizes the type of intervention, follow-up protocols, the outcome
measure, and the efficacy of each intervention included in the selected studies.
Nutrients 2017, 9, 161 7 of 14
Table 3. Intervention and follow-up protocol in the selected studies of dietary fiber treatment in symptomatic uncomplicated diverticular disease (SUDD).
Author, Year (Reference) Intervention FU (Months) Outcome Measure Efficacy of Intervention Adverse Effects
Lahner E., 2012 [22]
T1: High-fiber diet
T2: Symbiotic preparation +
high-fiber diet
6 Reduction ofabdominal symptoms
T1 and T2: decrease of abdominal pain <24 h
and >24 h in T1 and T2 (p < 0.05);
T1 and T2: decrease of intensity of abdominal
pain <24 h and bloating (p < 0.05)
None
Annibale B., 2011 [23]
T1: High-fiber diet
T2: Symbiotic (1 sachet bid) +
high-fiber diet for 14
days/months
T3: Symbiotic (2 sachets bid) +
high-fiber diet for 14
day/months
6 Reduction ofabdominal symptoms
T1: no significant efficacy; T2 and T3: decrease
of bloating VAS (p < 0.05),
and abdominal pain >24 h (p = 0.016)
T3: 1 pt diarrhea
Colecchia A., 2007 [24]
T1: Dietary fiber
T2: Dietary fiber + Rifaximin
400 mg bid for 7 days/months
24
Reduction of
abdominal symptoms
and diverticulitis
T1 and T2: significant reduction of symptomatic
score compared to baseline; T1 has similar
frequency of diverticulitis of T2
(4 pts in T1 vs. 2 pts in T2; p = 1)
Nausea, headache
and weakness,
T1: 3 pts, T2: 4 pts (p = ns)
Smits B.J., 1990 [25] T1: High-fiber dietT2: Lactulose 15 mL bid 3
Reduction of
abdominal symptoms
T1 and T2: reduction of abdominal pain
frequency (T1: p = 0.022 and T2 p = 0.0015) and
severity (T1: p = 0.028 and T2 p = 0.009) in
comparison to baseline
T1: none, T2 :4 pts drops
out for abdominal pain,
nausea, vomiting
Leahy A.L., 1985 [26] T1: High-fiber dietT2: Non High-fiber diet 65
Occurrence of symptoms
and diverticulitis
T1 reported fewer symptoms and surgery or
complications in comparison to T2 (19.3% vs.
44% and 6.4% vs. 32%; p < 0.05)
Not reported
Hyland J.M.P., 1980 [27] T1: High dietary fiber 60 Reduction ofabdominal symptoms T1: 91% (91/100) were symptoms free at 5 years Not reported
Brodribb A.J.M., 1977 [28] T1: Bran crispbreadT2: Wheat crispbread 3 Reduction of symptoms
T1 reduction of total symptom score in
comparison to T2 (from 34.3 to 8.1 and from 42.0
to 35.1 respectively p < 0.002)
Not reported
Plumley P.F., 1973 [29]
T1: High fiber crispbread
T2: Standard crispbread for at
least 2 months
21 Reduction ofabdominal symptoms
T1: 29/42 (69%) pts with pain were controlled
satisfactory. Only 14 pts took part in the cross
over trial (taking T2), but no results are available
Not reported
Painter N.S., 1972 [30] T1: High-residue, low sugardiet with unprocessed bran 22
Reduction of
abdominal symptoms T1: 88.6% of symptoms relieved or resolved
8 pts did not tolerate
bran diet
FU: follow-up; pts: patients; T1: treatment arm 1; T2: treatment arm 2; T3: treatment arm 3.
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Due to the poor quality of the studies and the heterogeneity of the study design (mean Jadad
score 1.5 ± 1.2 points), a meta-analysis could not be performed to provide a pooled estimate of the
outcome measure. With regard to adverse effects, data were not reported in four studies [26–29], no
adverse effect was observed in two studies [22–25], and in three studies, some minor effects were
reported [23,24,30].
3.5. Supplemental Fiber
These studies were performed over a range of 37 years, from 1976 to 2013, and just one article
was published in the last 10 years. Five studies were single center in nature [35,37–40] and five were
multicenter studies [31–34,36]. Five studies were conducted in the United Kingdom [35–37,39,40],
three in Italy [32–34], one in Spain [31], and one in the USA [38]. The ten included studies investigated
an overall total number of 1707 patients, of which 830 were female, but in three studies, the gender of
the patients was lacking [37–39]. Patients had a median age of 62 years, ranging from 54 to 66 years,
but in two studies, the age of patients was lacking [39,40].
With regard to the study type, three were open randomized controlled trials [31,32,34], two
were double blind-cross over studies [36,38], one was a double-blind randomized placebo controlled
study [33], two were open un-controlled studies [35,39], and the last was a cross-over RCT [40].
With regard to the type of supplementation, patients were treated with glucomannan [32,34],
ispaghula [35–37], bran [36–38,40], plantago ovata [31], and methylcellulose [38]. None of the studies
achieved a high dosage of fiber intake with the prescribed supplementation regimen. Because the fiber
intake of the diet was not reported, it may be that the total amount of the daily fiber intake is higher
than that reported. With regard to fiber solubility, soluble fibers were used in five studies [31–35], both
insoluble and soluble fibers were used in two studies [36,37], and in three studies, insoluble fibers
were used [38–40].
With regard to the follow-up protocol, the studies were variable, ranging from one to 12 months.
Five studies observed patients for a period of less than six months [35–38,40]. In addition, the
interventions were very variable: in four studies, fibers were administrated together with a drug
(rifaximin) and compared with the efficacy of the fiber alone [32–34]; in two studies, the efficacy of
ispaghula and bran was respectively compared to a placebo [36] or lactulose [37], or were administrated
as a unique arm of treatment in open un-controlled studies [35,39]. In another study, the efficacy of
bran was compared to a high roughage diet or bulk laxative [40], or methylcellulose was compared to
a placebo [38]. With regard to the outcome measures, the majority of studies evaluated the reduction
of abdominal symptoms [33,35–40], two evaluated the reduction of symptoms and the occurrence of
diverticulitis [32,34], and another study only considered the recurrence of diverticulitis [31]. In three
open RCTs, the efficacy of glucomannan (2 or 4 gr/day) was compared to glucomannan, together
with cyclic rifaximin, analysing the improvement of abdominal symptoms in SUDD patients [32–34].
In all three studies, a significant reduction of abdominal symptoms in the treatment arm with just
glucomannan was achieved. In two of these three studies, the glucomannan treatment arm had
a similar occurrence of diverticulitis to the antibiotic arm [33,34], while in the Latella study, the
glucomannan arm treatment reported more complications (p < 0.05) [32]. Table 4 summarizes the type
of intervention, follow-up protocols, outcome measures, and efficacy of interventions.
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Table 4. Intervention and follow-up protocol in the selected studies of supplemental fiber treatment in symptomatic uncomplicated diverticular disease (SUDD).
Author, Year (Reference) Intervention FU (Months) Outcome Measure Efficacy of Intervention Adverse Effects
Lanas A., 2013 [31]
T1: Plantago ovata 3.5 gr bid
T2: Plantago ovata 3.5 gr bid + Rifaximin
400 mg bid for 7 days/months
12 Recurrence of diverticulitis
T1: recurrences in 17/88 pts (19.3%) T2: recurrences in
8/77 (10.4%)
T1 had a significant higher risk of recurrence
p = 0.025; OR 3.2 (95% CI: 1.16–8.82)
T1: 13/88 (14.8%)
T2: 17/77 (22.1%)
(p = 0.225)
Latella G., 2003 [32]
T1: Glucomannan 4 gr/day
T2: Glucomannan 4 gr/day + Rifaximin
400 mg bid for 7 days/months
12
Reduction of abdominal
symptoms and occurrence
of diverticulitis
T1 and T2: significant reduction of global
symptomatic score in comparison to baseline;
T2 had more asymptomatic pts in comparison to T1:
29.2% vs. 56.5% pts at 12 months (p < 0.001);
T1 reported more diverticulitis in comparison to T2:
11 pts vs. 6 pts (p < 0.05).
Nausea, headache, and
asthenia:
T1: 5 (1.34%)
T2: 10 (1.68%)
(p = 0.7932)
Papi C., 1995 [33]
T1: Glucomannan 2 gr/die + placebo
T2: Glucomannan 2 gr/die + Rifaximin
400 mg bid for 7 days/month
12 Reduction ofabdominal symptoms
T1 and T2: reduction of global symptom score in
comparison to baseline;
T2 had more asymptomatic pts in comparison to T1:
68.9% vs. 39.5% pts at 12 month (p = 0.001);
No differences in preventing diverticulitis.
None
Papi C., 1992 [34]
T1: Glucomannan 2 gr/die
T2: Glucomannan 2 gr/die + Rifaximin
400 mg bid for 7 days/months
12
Reduction of abdominal
symptoms and occurrence
of diverticulitis
T1 and T2: reduction of global symptom score in
comparison to baseline. T2 had a marked reduction of
score in comparison to T1 (47.6% vs. 63.9%: p < 0.001);
No differences in preventing diverticulitis (T1: 3 vs.
T2: 0, p = 0.2467)
Not reported
Thorburn H.A., 1992 [35] T1: Ispaghula husk 1 Reduction ofabdominal symptoms
Improvement of abdominal pain in 71.4% (5/7);
Bowel habit improves in 66.6% (6/9) Not reported
Ornstein M.H., 1981 [36]
T1: Bran (6.99 gr/day)
T2: Ispaghula (9.04 gr/day)
T3: Placebo (2.34 gr/die)
4 Reduction ofabdominal symptoms
No change in pain. T1 and T2: improvement of
straining (p < 0.01)
T2: 2 pts diarrhea
T3: 1 pt constipation
Eastwood M.A., 1978 [37]
T1: Bran (20 gr/die)
T2: Ispaghula (2 sachets/day)
T3: Lactuose (20–40 mL/day)
1 Reduction ofabdominal symptoms T1, T2 and T3 alleviated symptoms Not reported
Hodgson W.J.B., 1977 [38] T1: Methylcellulose 500 mg bidT2: Placebo 3
Reduction of abdominal
symptoms
Symptoms score decrease significantly in T1 (from
19 ± 6, to 13 ± 4 p < 0.01) but not in T2 (from 21 ± 7 to
17 ± 9, p = ns)
Not reported
Brodribb A.J.M., 1976 [39] T1:Wheat bran 24 gr/die 6 Reduction ofabdominal symptoms 60% of symptoms were abolished and 28% relieved Not reported
Taylor I., 1976 [40]
T1: High roughage diet with
bran supplement
T2: Bulk laxative plus antispasmodic
T3: Bran tablets (18 gr/day)
2 Reduction ofabdominal symptoms
T3 was most effective in reduce symptoms.
Asymptomatics pts were:
T1 = 20%; T2 = 40%; T3 = 60%
Not reported
FU: follow-up; pts: patients; T1: treatment arm 1; T2: treatment arm 2; T3: treatment arm 3.
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Also, due to the poor quality of the studies and their heterogeneity (mean Jadad score
1.9 ± 1.8 points), a meta-analysis could not be performed.
On the basis of the heterogeneity of these papers, it was not possible to perform a sub-analysis
assessing the differences between dietary and supplemental fibers, the effects of high- or low fiber
diet/supplementation, or the differences between soluble and insoluble fibers.
With regard to adverse effects, data were not reported in six studies [34,35,37–40], some minor
adverse effects were reported in the fiber arm in three studies [31,32,36], and in another study, the only
double-blind randomized placebo controlled report, no adverse effects were observed [33].
4. Discussion
Dietary fibers are defined as the edible parts of plants or the analogous carbohydrates
that are resistant to digestion and absorption in the human small intestine, with complete or
partial fermentation in the colon [15]. Dietary fibers include non-starch polysaccharides, resistant
oligosaccharides, and other carbohydrates, such as resistant starch and dextrins, and lignin [41,42].
Non-starch polysaccharides can be further subdivided into soluble and insoluble fibers: soluble fibers
dissolve in water-forming viscous gels, bypass the digestion of the small intestine, and are easily
fermented by the gut microbiota (i.e., pectins, gums, inulin-type fructans, and some hemicelluloses).
In contrast, insoluble fibers are not water soluble, they do not form gels due to their water insolubility,
and fermentation is severely limited (i.e., lignin, cellulose, and some hemicelluloses). The Academy of
Nutrition and Dietetics declared that the adequate intake of fiber is 14 gr total per 1000 kcal, or 25 gr for
adult women and 38 gr for adult men [18]. In Western countries, the daily fiber intake can change from
region to region, and may change over the years. The mean intake of dietary fiber in the United States
is 17 gr/day, with only 5% of the general population meeting the adequate intake [18]. In contrast, in
a recent study evaluating the changes in food consumption and nutrient intake in a Mediterranean
cohort, it has been observed that fiber intake has a baseline of 24.3 ± 9.4 gr/day; after 10 years, it
was observed that fiber intake increased by 1.8 gr/day, thus augmenting over time [43]. Even if the
health benefits of dietary fibers have long been appreciated, especially for their effect on cardiovascular
diseases, type II diabetes, glycemic control, and gastrointestinal conditions [14], these data underline
that dietary habits in Western countries may be far from the recommended adequate intake.
With regard to the risk of developing colonic diverticula, it has been proposed that “fiber
deficiency”, caused by the spreading of refined carbohydrates in the Western diet, may play an
important role. However, little evidence is available to substantiate this hypothesis [44,45], and more
recently, this concept has been reviewed. A colonoscopy-based, cross-sectional study on the dietary
risk factors for diverticulosis found that a high fiber diet was even associated with a higher prevalence
of colonic diverticula [46]. The association with dietary fiber intake was dose-dependent and stronger
when limited to cases with multiple diverticula. Although it has been suggested that a high-fiber
diet does not protect against the development of colonic diverticulosis, it may reduce the abdominal
symptoms related to diverticular disease.
Patients with SUDD may complain of chronic recurrent abdominal symptoms, and fibers might
confer benefits by increasing fecal mass and promoting the regularity of bowel movements. Another
beneficial effect of fibers in the treatment of SUDD may be ascribed to their capability to act as prebiotics
in the colon, by favoring health-promoting species of the intestinal microbiota, especially bifidobacteria
and lactobacilli [14].
Diverticular disease is a complex, multifactorial disorder, in which the gut microbiota could
play a key role. Recently, Barbara et al. reported that patients with diverticular disease showed
depletion of microbiota members with anti-inflammatory properties, including Clostridium cluster IV,
Clostridium cluster IX, Fusobacterium, and Lactobacillaceae, with microbiota changes being correlated
with mucosal immune activation [47]. The gut microbiota, indeed, shifts rapidly in response to dietary
changes, particularly with fiber intake [48]. For this reason, high-fiber intake represents a promising
treatment option in diverticular disease. In this condition, a high-fiber diet based on fruits, vegetables,
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and cereal grains may be difficult to achieve and should be supported with an adequate dietary
counseling, and in a subset of patients, the use of supplemental fibers might be useful.
The beneficial effect on potential microbiota changes achieved with dietary fibers, based on
different amounts of soluble and insoluble fibers, or the supplementation of commercial fibers of the
same type, may be different and not necessarily comparable. However, it was not possible to perform
a sub-analysis assessing the differences between dietary or supplemental fibers, or between high- or
low-fiber diet/supplementation. Unfortunately, on the basis of these studies, it was not possible to
assess differences between the effect of soluble or insoluble fibers, even if the relative amount might
have influenced the outcome of treatment. In patients with irritable bowel syndrome, a condition that
might be considered similar to SUDD, the effect of fibers appears to be limited to the soluble type [49].
In clinical practice, a high-fiber diet or fiber supplementation are commonly used in patients
affected by diverticular disease, even if most recommendations are based on poor evidence. A previous
systematic review, performed in 2012, was restricted to the use of a high-fiber diet in diverticular
disease and only included controlled studies in the English language, reporting that high-quality
evidence for a high-fiber diet in the treatment of this condition is scarce [16].
The present systematic review represents an attempt to provide an updated measure of evidence
on the efficacy of dietary and supplemental fibers in SUDD, in terms of the reduction of abdominal
symptoms and the prevention of acute diverticulitis.
The research was updated until October 2016, considering randomized controlled trials (blinded
and/or placebo-controlled), open randomized clinical trials, non-randomized open studies, and also
taking into consideration papers in German, French, Italian, and Spanish. The selected studies, all of
which came from Western countries with just one study from the USA, presented a high heterogeneity
concerning the quantity and quality of the fibers employed, notwithstanding dietary and supplemental
fibers, which were evaluated separately. However, the quality of the studies was very low, with just
one study yielding an optimal score [33]. Based on the available studies, it was not possible to draw
conclusions regarding the efficacy of fiber treatment in SUDD patients, neither in terms of the reduction
of abdominal symptoms, nor for the prevention of acute diverticulitis.
5. Conclusions
Single low quality studies suggest that fibers, both dietary and supplemental, could be beneficial
in the treatment of SUDD. The presence of substantial methodological limitations, the heterogeneity of
therapeutic regimens employed, and the lack of ad hoc designed studies, do not permit a summary
of the outcome measures. Up to now, high-quality evidence on the efficacy of fiber treatment for the
reduction of symptoms in SUDD and for the prevention of acute diverticulitis, is lacking. Thus, further,
well-designed studies, specifically focusing on the efficacy of fibers in SUDD, dietary or supplemental,
are needed.
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